Premium
Effective and safe tumor inhibition using vinblastine in medulloblastoma
Author(s) -
Nobre Liana,
Pauck David,
Golbourn Brian,
Maue Mara,
Bouffet Eric,
Remke Marc,
Ramaswamy Vijay
Publication year - 2019
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.27694
Subject(s) - vincristine , medulloblastoma , medicine , vinblastine , peripheral neuropathy , chemotherapy , oncology , toxicity , pharmacology , cancer research , cyclophosphamide , endocrinology , diabetes mellitus
Most medulloblastoma protocols worldwide include vincristine during radiation and chemotherapy. A significant dose‐limiting toxicity is peripheral neuropathy; however, there is a paucity of data to support the view that omission of vincristine does not impact survival. Herein we report two adolescent patients with Group 4 and SHH medulloblastoma, where vinblastine successfully replaced vincristine with resolution of their peripheral neuropathy. We furthermore show vinblastine is highly active in vitro and demonstrates equivalent antitumoral activity compared to vincristine. Substitution of vincristine with vinblastine in future studies should be considered for all patients with medulloblastoma, particularly those with hereditary neuropathy, severe vincristine toxicity, and adults.